X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Biocon Ltd with GSK Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

BIOCON vs GSK PHARMA - Comparison Results

BIOCON     Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

GSK PHARMA 
   Change

GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    BIOCON GSK PHARMA BIOCON /
GSK PHARMA
 
P/E (TTM) x 40.9 53.6 76.3% View Chart
P/BV x 7.1 10.6 66.8% View Chart
Dividend Yield % 0.2 2.7 6.0%  

Financials

 BIOCON    GSK PHARMA
EQUITY SHARE DATA
    BIOCON
Mar-18
GSK PHARMA
Mar-18
BIOCON /
GSK PHARMA
5-Yr Chart
Click to enlarge
High Rs1,1882,760 43.0%   
Low Rs3052,040 15.0%   
Sales per share (Unadj.) Rs68.7339.0 20.3%  
Earnings per share (Unadj.) Rs7.641.4 18.2%  
Cash flow per share (Unadj.) Rs14.045.9 30.4%  
Dividends per share (Unadj.) Rs1.0035.00 2.9%  
Dividend yield (eoy) %0.11.5 9.2%  
Book value per share (Unadj.) Rs86.3242.9 35.5%  
Shares outstanding (eoy) m600.0084.70 708.4%   
Bonus/Rights/Conversions IS--  
Price / Sales ratio x10.97.1 153.4%   
Avg P/E ratio x98.957.9 170.6%  
P/CF ratio (eoy) x53.452.3 102.2%  
Price / Book Value ratio x8.69.9 87.5%  
Dividend payout %13.284.5 15.7%   
Avg Mkt Cap Rs m447,900203,280 220.3%   
No. of employees `0006.1NA-   
Total wages/salary Rs m9,3115,234 177.9%   
Avg. sales/employee Rs Th6,705.8NM-  
Avg. wages/employee Rs Th1,514.2NM-  
Avg. net profit/employee Rs Th736.9NM-  
INCOME DATA
Net Sales Rs m41,23428,715 143.6%  
Other income Rs m2,062545 378.1%   
Total revenues Rs m43,29629,260 148.0%   
Gross profit Rs m8,2915,059 163.9%  
Depreciation Rs m3,851380 1,013.4%   
Interest Rs m6152 30,750.0%   
Profit before tax Rs m5,8875,222 112.7%   
Minority Interest Rs m2130-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0178 0.0%   
Tax Rs m1,5691,892 82.9%   
Profit after tax Rs m4,5313,508 129.2%  
Gross profit margin %20.117.6 114.1%  
Effective tax rate %26.736.2 73.6%   
Net profit margin %11.012.2 89.9%  
BALANCE SHEET DATA
Current assets Rs m41,48621,815 190.2%   
Current liabilities Rs m21,41315,999 133.8%   
Net working cap to sales %48.720.3 240.3%  
Current ratio x1.91.4 142.1%  
Inventory Days Days6464 100.6%  
Debtors Days Days9419 504.0%  
Net fixed assets Rs m50,66112,475 406.1%   
Share capital Rs m3,000847 354.2%   
"Free" reserves Rs m48,80819,726 247.4%   
Net worth Rs m51,80820,573 251.8%   
Long term debt Rs m17,8986 298,300.0%   
Total assets Rs m99,89739,475 253.1%  
Interest coverage x10.62,612.0 0.4%   
Debt to equity ratio x0.30 118,456.8%  
Sales to assets ratio x0.40.7 56.7%   
Return on assets %5.28.9 57.9%  
Return on equity %8.717.1 51.3%  
Return on capital %9.626.2 36.7%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m12,058564 2,137.9%   
Fx outflow Rs m7,3487,429 98.9%   
Net fx Rs m4,710-6,865 -68.6%   
CASH FLOW
From Operations Rs m6,6214,728 140.0%  
From Investments Rs m-6,840-1,042 656.5%  
From Financial Activity Rs m-2,397-3,066 78.2%  
Net Cashflow Rs m-2,612620 -421.5%  

Share Holding

Indian Promoters % 40.4 0.0 -  
Foreign collaborators % 20.6 50.7 40.6%  
Indian inst/Mut Fund % 8.4 10.2 82.4%  
FIIs % 10.7 23.8 45.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 19.9 15.4 129.2%  
Shareholders   109,995 102,036 107.8%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare BIOCON With:   STRIDES PHARMA SCIENCE  ELDER PHARMA  ALEMBIC LTD  ALEMBIC PHARMA  CADILA HEALTHCARE  

Compare BIOCON With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trades Marginally Higher; Tata Motors Slips 5%(12:30 pm)

Share markets in India are presently trading on a positive note. Sectoral indices are trading mixed with stocks in the realty sector, oil & gas sector.

Related Views on News

GSK PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 26.0% (Quarterly Result Update)

Feb 5, 2019 | Updated on Feb 5, 2019

For the quarter ended December 2018, GSK PHARMA has posted a net profit of Rs 1 bn (up 26.0% YoY). Sales on the other hand came in at Rs 8 bn (up 17.3% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

BIOCON LTD Announces Quarterly Results (3QFY19); Net Profit Up 169.2% (Quarterly Result Update)

Jan 28, 2019 | Updated on Jan 28, 2019

For the quarter ended December 2018, BIOCON LTD has posted a net profit of Rs 2 bn (up 169.2% YoY). Sales on the other hand came in at Rs 15 bn (up 45.6% YoY). Read on for a complete analysis of BIOCON LTD's quarterly results.

BIOCON LTD Announces Quarterly Results (2QFY19); Net Profit Up 501.9% (Quarterly Result Update)

Nov 9, 2018 | Updated on Nov 9, 2018

For the quarter ended September 2018, BIOCON LTD has posted a net profit of Rs 4 bn (up 501.9% YoY). Sales on the other hand came in at Rs 13 bn (up 36.4% YoY). Read on for a complete analysis of BIOCON LTD's quarterly results.

GSK PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 22.7% (Quarterly Result Update)

Oct 23, 2018 | Updated on Oct 23, 2018

For the quarter ended September 2018, GSK PHARMA has posted a net profit of Rs 1 bn (down 22.7% YoY). Sales on the other hand came in at Rs 8 bn (down 2.4% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

BIOCON LTD Announces Quarterly Results (1QFY19); Net Profit Up 47.2% (Quarterly Result Update)

Jul 30, 2018 | Updated on Jul 30, 2018

For the quarter ended June 2018, BIOCON LTD has posted a net profit of Rs 1 bn (up 47.2% YoY). Sales on the other hand came in at Rs 11 bn (up 20.4% YoY). Read on for a complete analysis of BIOCON LTD's quarterly results.

More Views on News

Most Popular

This is Why the Stock of Jubilant FoodWorks Went Up 1,160%(The 5 Minute Wrapup)

Apr 12, 2019

This critical business strategy has enabled companies to scale their operations faster.

Pocketing Massive Gains with HDFC And HDFC Bank(Profit Hunter)

Apr 12, 2019

Here's how one could have generated gains of Rs 59,250 in 10 days by trading HDFC and HDFC Bank with a capital of Rs 4 lakh.

A Simple 3-Point Investing Manifesto for You the Indian Investor(The 5 Minute Wrapup)

Apr 11, 2019

A must have checklist for every investor in the Indian stock market.

My Master Series on How to Trade Election 2019(Profit Hunter)

Apr 16, 2019

For 30 years he has watched how elections impact the markets, and practiced how to profit from it. Now he is here...telling you everything. Read on...

Election Series: Follow the World's Biggest Traders To See Where the Money Flows(The 5 Minute Wrapup)

Apr 17, 2019

20% of all the traders bring in 80% of the money. Watch these 20% and you get a working idea of which way the wind is blowing.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

BIOCON SHARE PRICE


Apr 24, 2019 01:47 PM

TRACK BIOCON

COMPARE BIOCON WITH

MARKET STATS